VEGFA and colorectal carcinoma: At present, different targeted treatment options are available for metastatic CRC patients, including monoclonal antibodies against the vascular endothelial growth factor (VEGF) or the epidermal growth factor receptor (EGFR), either as monotherapy, combined with chemotherapy, or with each other, to enhance patients’ progression-free survival or overall survival [27,28].